查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1987136

肝病治療市場規模、佔有率、趨勢和預測：按治療方法、疾病、最終用戶和地區分類，2026-2034 年

Liver Disease Treatment Market Size, Share, Trends and Forecast by Treatment Type, Disease Type, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2025年全球肝病治療市場規模為265億美元。預計到2034年，該市場規模將達到417億美元，2026年至2034年的複合年成長率（CAGR）為5.02%。北美目前在該市場主導，2025年市佔率為38.6%。全球老年人口不斷成長，易患多種慢性疾病，包括肝病，這對市場發展起到了積極作用。此外，製藥業的蓬勃發展和技術的不斷進步也推動了肝病治療市場的成長。

肝病治療市場趨勢：

人們越來越關注非酒精性脂肪肝

隨著肥胖和糖尿病的日益流行，非酒精性脂肪肝病（NAFLD）已成為肝病治療的重點。例如，根據國際糖尿病聯盟（IDF）發布的《糖尿病地圖集（2025）》，11.1%的成年人（20-79歲）患有糖尿病，即每9人中就有1人患有糖尿病，而其中超過40%的人並不知道自己已被診斷出患有糖尿病。由於NAFLD早期通常無症狀，因此可能發展為嚴重的併發症，這使得對有效治療方法的需求日益迫切。醫療系統正在應用先進的影像技術、生物標記和篩檢項目，以期更早發現該疾病。製藥公司正在優先進行新療法的臨床試驗，而醫療服務提供者則強調個人化治療方案，包括飲食指導和生活方式介入。此外，公共衛生工作正在提高大眾對NAFLD風險的認知，從而提高患者的參與度和治療接受度。

人們越來越關注製藥領域的擴張

製藥業的蓬勃發展正透過加速創新、提高藥物可及性以及拓展全球治療選擇，推動肝病治療市場的成長。製藥公司正迅速投資研發治療肝病的新藥。例如，總部位於印度的製藥公司Zydus Lifesciences於2024年2月宣布，計劃於2026年初在美國推出首款新藥，旨在進軍價值數十億美元的特定類型肝病治療市場。各公司正增加研發預算、建立策略聯盟並收購中小型生技公司，以獲取先進治療方法和新型候選藥物。這種擴張還包括擴大生產能力以滿足不斷成長的需求，以及改善分銷網路以覆蓋服務不足的地區。監管機構正在簡化突破性治療方法的核准流程，以加快藥物上市速度。

肝臟移植需求增加

肝臟移植需求的不斷成長是肝病治療市場的主要趨勢之一。隨著許多肝病患者病情發展至末期肝功能衰竭的需求日益增加。微創手術技術和術後照護的改進等技術進步，使肝臟移植手術更加普及。政府機構和私人醫療機構正在投資基礎建設和經濟援助項目，以降低肝臟移植手術的成本。 2024年5月，沃克哈特醫院與南亞肝臟研究所合作，在孟買啟動了肝臟移植早期復健計畫（ERP）。該計劃旨在將肝臟移植手術的成本降低約20-30%。人們對肝臟移植成功率的認知不斷提高，以及捐贈者配對技術的改進，促使更多患者選擇接受肝臟移植手術。器官保存技術的進步和更有效的免疫抑制劑的出現，提高了患者的生存率和康復效果，進一步促進了肝臟移植手術的普及。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球肝病治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療方法分類

  • 抗病毒藥物
  • 免疫抑制劑
  • 疫苗
  • 免疫球蛋白
  • 皮質類固醇
  • 標靶治療
  • 化療

第7章 市場區隔：依疾病分類

  • 肝炎
  • 自體免疫疾病
  • 非酒精性脂肪肝（NAFLD）
  • 癌症
  • 遺傳性疾病
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 門診手術中心
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
Product Code: SR112026A5023

The global liver disease treatment market size was valued at USD 26.5 Billion in 2025. The market is projected to reach USD 41.7 Billion by 2034, exhibiting a CAGR of 5.02% from 2026-2034. North America currently dominates the market, holding a market share of 38.6% in 2025. The growing elderly population worldwide, which is prone to several chronic illnesses, including liver disease, is positively influencing the market. Besides this, rising emphasis on pharmaceutical expansion and ongoing technological advancements are propelling the liver disease treatment market share.

LIVER DISEASE TREATMENT MARKET ANALYSIS:

  • Major Market Drivers: The fluctuating dietary habits and physical inactivity are propelling the market.
  • Key Market Trends: The improving research and development activities, major growth in the healthcare industry, and the adoption of numerous government programs to promote public health are a few factors contributing to the liver disease treatment market growth.
  • Competitive Landscape: Some of the major market companies include Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Viatris Inc., among many others.
  • Geographical Trends: North America is currently dominating the market as a result of a rise in liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and hepatitis, especially considering an upsurge in obesity and diabetes rates, which are major risk factors for liver conditions.
  • Challenges and Opportunities: The high cost of advanced therapies, which limits patient access, is hampering the market. However, increasing government financing, enhancing insurance coverage, and encouraging research into more affordable treatment options will continue to catalyze the market over the forecast period.

The market is driven by the rising prevalence of conditions, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer, fueled by changing lifestyles, alcohol consumption, and increasing obesity rates. Heightened consciousness about early detection and accessibility of advanced treatment alternatives is catalyzing the demand. The development of innovative drugs, targeted therapies, and minimally invasive surgical procedures is expanding the treatment landscape. Supportive government initiatives, improved healthcare infrastructure, and wider availability of medical insurance policies are encouraging more patients to seek treatment. Additionally, an increase in liver transplants and advancements in immunosuppressive therapies are improving patient outcomes.

The United States has emerged as a major region in the liver disease treatment market owing to many factors. The high prevalence of chronic liver conditions, such as hepatitis C, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver disorders, is offering a favorable liver disease treatment market outlook. Increasing obesity rates and sedentary lifestyles are contributing to NAFLD growth, while aging population is facing higher risks of liver complications. As per the data from Cosmos, the percentage of obesity among US adults rose by 13.6% from 2010 to 2024. Strong healthcare infrastructure, widespread insurance coverage, and advanced diagnostic facilities are enabling early detection and treatment adoption. Significant research and development (R&D) investments, especially in targeted therapies and antiviral drugs, are enhancing treatment effectiveness.

LIVER DISEASE TREATMENT MARKET TRENDS:

Increased Focus on NAFLD

With the rise of obesity and diabetes, NAFLD has become a primary focus in liver disease treatment. For instance, the International Diabetes Federation (IDF) Diabetes Atlas (2025) indicated that 11.1%, or 1 in 9 adults (20-79 years), were affected by diabetes, with more than 4 in 10 unaware about their diagnosis. NAFLD, often asymptomatic in its early stages, can progress to severe complications, driving a strong demand for effective interventions. Healthcare systems are integrating advanced imaging techniques, biomarkers, and screening programs to detect the condition sooner. Pharmaceutical firms are prioritizing clinical trials for novel therapeutics, while healthcare providers are emphasizing personalized treatment approaches, including dietary guidance and lifestyle modification support. Public health initiatives are also generating awareness about NAFLD risks, leading to increased patient engagement and treatment uptake.

Growing Emphasis on Pharmaceutical Expansion

Rising emphasis on pharmaceutical expansion is impelling the liver disease treatment market growth by accelerating innovations, improving drug availability, and broadening treatment options globally. Pharmaceutical companies are rapidly investing in the discovery of new medications to treat liver illnesses. For instance, in February 2024, Zydus Lifesciences, a pharmaceutical firm based in India, declared its intention to introduce its inaugural new drug in the United States by early 2026, aiming to enter the multi-billion-dollar market for treating a specific type of liver disease. Companies are increasing R&D budgets, forming strategic collaborations, and acquiring smaller biotech firms to gain access to advanced therapies and novel drug candidates. This expansion also involves scaling up manufacturing capabilities to meet rising demand and improving distribution networks to reach underserved regions. Regulatory agencies are streamlining approval processes for breakthrough therapies, enabling faster market entry.

Rising Demand for Liver Transplants

Escalating demand for liver transplants is among the major liver disease treatment market trends. As liver disease is advancing to end-stage liver failure in many people, the demand for liver transplants is growing. Transplants are becoming more accessible owing to technological advancements, such as minimally invasive methods and enhanced post-operative care. Government agencies and private healthcare providers are investing in infrastructure and financial assistance programs to make transplants more accessible. In May 2024, Wockhardt Hospitals, together with the South Asian Liver Institute, initiated an early recovery program (ERP) for liver transplants in Mumbai. The initiative sought to lessen the financial impact of liver transplants by around 20-30%. Rising awareness about transplant success rates and improved donor matching technologies are encouraging more patients to opt for this procedure. Enhanced organ preservation methods and better immunosuppressive drugs are refining patient survival and recovery outcomes, further boosting acceptance.

LIVER DISEASE TREATMENT INDUSTRY SEGMENTATION:

Analysis by Treatment Type:

  • Antiviral Drugs
  • Immunosuppressants
  • Vaccines
  • Immunoglobulins
  • Corticosteroids
  • Targeted Therapy
  • Chemotherapy

Antiviral drugs held 39.8% of the market share in 2025. They are gaining popularity due to their critical role in managing viral hepatitis, particularly hepatitis B and C, which are among the most common causes of liver disorders worldwide. These drugs effectively reduce viral load, slow disease progression, and lower the risk of severe complications, such as cirrhosis and liver cancer. The availability of highly potent and well-tolerated direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment, offering high cure rates with shorter treatment durations. In addition, the ongoing R&D activities have resulted in improved formulations with fewer side effects, boosting patient compliance. Widespread screening programs and increased awareness about early detection of viral hepatitis have also supported the dominance of antiviral drugs. Furthermore, government initiatives, global health campaigns, and inclusion of antivirals in reimbursement schemes have expanded patient access. Their proven efficacy, strong clinical guidelines, and large target patient population firmly position antiviral drugs as the leading treatment type in the market.

Analysis by Disease Type:

  • Hepatitis
  • Autoimmune Diseases
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Cancer
  • Genetic Disorders
  • Others

Hepatitis accounts for the largest market share. It represents one of the most prevalent and widely diagnosed liver conditions globally, spread primarily by hepatitis viruses A, B, C, D, and E. Chronic hepatitis B and C cause significant issues to public health, affecting millions and significantly increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. The high disease burden is driving substantial demand for diagnostic services, antiviral drugs, and ongoing patient monitoring. Advancements in DAAs and other targeted therapies have transformed treatment outcomes, particularly for hepatitis C, with high cure rates and improved safety profiles. Government-led vaccination programs for hepatitis B and awareness campaigns for early detection have also expanded diagnosis rates and treatment adoption. Additionally, global health initiatives and inclusion of hepatitis management in national healthcare priorities ensure strong funding and access to therapies. The combination of high prevalence, severe health risks, and effective treatment options positions hepatitis as the dominant segment in the market.

Analysis by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Hospitals hold 38.9% of the market share. They offer comprehensive facilities for diagnosis, advanced treatment, and post-treatment care, making them the primary choice for managing complex liver conditions. Liver diseases, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer, often require multidisciplinary care involving hepatologists, gastroenterologists, radiologists, and surgeons, which hospitals are best equipped to provide. They have access to advanced imaging technologies, laboratory testing, and surgical infrastructure, including liver transplantation units, which are critical for severe cases. Hospitals also ensure immediate access to emergency care for acute liver failure and complications. Moreover, government and private healthcare investments in hospital infrastructure, along with improved reimbursement policies, are enhancing treatment accessibility and patient trust. As per the liver disease treatment market forecast, the capacity of hospitals to handle both inpatient and outpatient services will continue to strengthen their dominance in the segment.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for a share of 38.6%, enjoys the leading position in the market. The area is recognized for its developed healthcare facilities, substantial healthcare spending, and significant presence of prominent pharmaceutical and biotechnology companies. The region has a high prevalence of liver disorders, such as NAFLD, hepatitis, and liver cancer, which is driving strong demand for effective treatments. As per the projections of Liver Canada, in 2024, there were set to be around 4700 new instances of liver and intrahepatic bile duct cancer in Canada. Robust R&D activities, supported by significant funding from both government and private sectors, are fostering innovations in novel therapies, including targeted drugs, biologics, and regenerative solutions. In addition, the widespread adoption of advanced diagnostic tools, the availability of skilled healthcare professionals, and strong awareness programs are contributing to early detection and treatment.

KEY REGIONAL TAKEAWAYS:

UNITED STATES LIVER DISEASE TREATMENT MARKET ANALYSIS

The United States holds 88.70% of the market share in North America. The United States is witnessing increased liver disease treatment adoption primarily due to the rising burden of chronic illnesses. Conditions, such as obesity, type 2 diabetes, and hypertension, are escalating, directly contributing to the development of liver disorders like NAFLD and cirrhosis. For instance, almost 75% of adults in the US were classified as overweight or obese, based on a 2024 study. The demand for advanced therapeutics and diagnostics is expanding, as patients are seeking timely intervention and disease management. This trend is further supported by heightened awareness campaigns, improved healthcare access, and the emphasis on early detection. Moreover, medical advancements in liver-related therapies are encouraging the use of proactive treatment approaches. Pharmaceutical investments and clinical trials are also bolstering innovations in liver treatment. The continuous rise in chronic illnesses ensures steady growth in treatment requirements, highlighting a strong healthcare focus on combating liver-related complications.

EUROPE LIVER DISEASE TREATMENT MARKET ANALYSIS

Europe is witnessing steady growth in liver disease treatment adoption due to a rapidly expanding geriatric population. According to the WHO, the demographic of individuals aged 60 and above increased in the WHO European Region. In 2021, the number was 215 Million. By 2030, it is expected to reach 247 Million and by 2050, it will surpass 300 Million. Aging individuals are increasingly vulnerable to liver conditions, such as fibrosis, hepatitis, and cirrhosis, as age-related metabolic changes heighten susceptibility. The regional healthcare system is evolving to meet the specific needs of older patients, incorporating specialized diagnostics, monitoring, and therapeutic approaches. Government-supported healthcare programs are enabling better access to treatment for elderly individuals affected by liver dysfunction. Medical technology tailored for geriatric care, including minimally invasive procedures and personalized medication regimens, is also playing a key role.

ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET ANALYSIS

The Asia-Pacific region is experiencing market expansion, driven by the growing demand for liver transplants. For instance, as of March 2025, in India, the success rate for liver transplants was 85% within one year and 75% after five years. An increasing incidence of liver failure and end-stage liver disease is resulting in heightened transplant requirements across the region. Lifestyle changes, viral hepatitis prevalence, and alcohol-related liver damage are contributing significantly to this need. The medical infrastructure is expanding, and transplant procedures are becoming more accessible and technologically advanced. Improvements in donor management and transplantation techniques are making treatment more effective and widely available. Public and private sectors are collaborating to enhance transplant centers and organ donation networks. Additionally, awareness programs around transplantation and liver health are influencing patient decisions.

LATIN AMERICA LIVER DISEASE TREATMENT MARKET ANALYSIS

In Latin America, the market is seeing a notable rise in liver disease treatment adoption due to increasing cases of liver cancer and genetic disorders. For instance, in Brazil, the anticipated cancer prevalence for the 2023-2025 period was 704,000 new cases. These health challenges are contributing significantly to liver complications requiring ongoing medical intervention. Genetic predispositions and liver-related malignancies are catalyzing greater demand for diagnostics, therapies, and disease management programs across the region.

MIDDLE EAST AND AFRICA LIVER DISEASE TREATMENT MARKET ANALYSIS

The Middle East and Africa region is experiencing the growth of the market, fueled by expanding healthcare facilities. For instance, in 2025, the UAE hosted more than 150 hospitals and contained over 5,000 healthcare facilities. New hospitals, clinics, and specialized care centers are being established, offering improved access to diagnostic tools and therapeutic services. Infrastructure development is enabling earlier detection and intervention, promoting better liver health outcomes for patients across diverse populations.

COMPETITIVE LANDSCAPE:

Key players are investing heavily in R&D activities to introduce advanced drugs, biologics, and innovative therapies targeting various liver disorders. They are focusing on developing more effective, safer, and targeted treatment options, including antivirals, immunotherapies, and regenerative solutions. Strategic collaborations with research institutes, biotechnology firms, and healthcare providers are accelerating drug discovery and clinical trials. These companies also engage in mergers, acquisitions, and licensing agreements to expand product portfolios and geographic reach. By launching awareness programs, patient support initiatives, and affordable treatment schemes, they are enhancing access to care. Furthermore, their continuous investments in technology, including AI-based drug discovery and precision medicine, help address unmet medical needs and improve patient outcomes in liver disease management. For instance, in April 2025, the US FDA granted approval for Opdivo(R) in combination with Yervoy(R) as a first-line therapy for liver disease in cases of unresectable or metastatic hepatocellular carcinoma, based on Phase 3 CheckMate-9DW trial findings demonstrating improved overall survival compared to lenvatinib or sorafenib. In the study, 38% of patients treated with the immunotherapy combination survived at three years, while 24% were alive in the comparison group.

The report provides a comprehensive analysis of the competitive landscape in the liver disease treatment market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the liver disease treatment market?

2. What is the future outlook of liver disease treatment market?

3. What are the key factors driving the liver disease treatment market?

4. Which region accounts for the largest liver disease treatment market share?

5. Which are the leading companies in the global liver disease treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Liver Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Antiviral Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Vaccines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunoglobulins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Corticosteroids
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Targeted Therapy
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Chemotherapy
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Hepatitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Non-alcoholic Fatty Liver Disease (NAFLD)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Genetic Disorders
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AbbVie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Astellas Pharma Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Emergent BioSolutions Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Gilead Sciences Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 GlaxoSmithKline plc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck & Co. Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novartis AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Sanofi S.A.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis
    • 14.3.14 Takeda Pharmaceutical Company Limited
      • 14.3.14.1 Company Overview
      • 14.3.14.2 Product Portfolio
      • 14.3.14.3 Financials
      • 14.3.14.4 SWOT Analysis
    • 14.3.15 Viatris Inc.
      • 14.3.15.1 Company Overview
      • 14.3.15.2 Product Portfolio
      • 14.3.15.3 Financials

List of Figures

  • Figure 1: Global: Liver Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Liver Disease Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Liver Disease Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Liver Disease Treatment Market: Breakup by Treatment Type (in %), 2025
  • Figure 5: Global: Liver Disease Treatment Market: Breakup by Disease Type (in %), 2025
  • Figure 6: Global: Liver Disease Treatment Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Liver Disease Treatment Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Liver Disease Treatment (Antiviral Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Liver Disease Treatment (Antiviral Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Liver Disease Treatment (Immunosuppressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Liver Disease Treatment (Immunosuppressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Liver Disease Treatment (Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Liver Disease Treatment (Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Liver Disease Treatment (Immunoglobulins) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Liver Disease Treatment (Immunoglobulins) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Liver Disease Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Liver Disease Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Liver Disease Treatment (Targeted Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Liver Disease Treatment (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Liver Disease Treatment (Chemotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Liver Disease Treatment (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Liver Disease Treatment (Hepatitis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Liver Disease Treatment (Hepatitis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Liver Disease Treatment (Autoimmune Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Liver Disease Treatment (Autoimmune Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Liver Disease Treatment (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Liver Disease Treatment (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Liver Disease Treatment (Genetic Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Liver Disease Treatment (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Liver Disease Treatment (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Liver Disease Treatment (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Liver Disease Treatment (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Liver Disease Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Liver Disease Treatment (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Liver Disease Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: North America: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: North America: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United States: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United States: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Canada: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Canada: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Asia-Pacific: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Asia-Pacific: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: China: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: China: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Japan: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Japan: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: India: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: India: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: South Korea: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: South Korea: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Australia: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Australia: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Indonesia: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Indonesia: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Europe: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Europe: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Germany: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Germany: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: France: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: France: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: United Kingdom: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: United Kingdom: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Italy: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Italy: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Spain: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Spain: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Russia: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Russia: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Latin America: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Latin America: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Brazil: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Brazil: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Mexico: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Mexico: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Others: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Middle East and Africa: Liver Disease Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Middle East and Africa: Liver Disease Treatment Market: Breakup by Country (in %), 2025
  • Figure 88: Middle East and Africa: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Global: Liver Disease Treatment Industry: SWOT Analysis
  • Figure 90: Global: Liver Disease Treatment Industry: Value Chain Analysis
  • Figure 91: Global: Liver Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Liver Disease Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Liver Disease Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Liver Disease Treatment Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 4: Global: Liver Disease Treatment Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Liver Disease Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Liver Disease Treatment Market: Competitive Structure
  • Table 7: Global: Liver Disease Treatment Market: Key Players